SOPHiA GENETICS announces proposed public share offering

SOPHiA GENETICS (NASDAQ: SOPH) announced a proposed underwritten public offering of its ordinary shares, according to a company press release dated June 16, 2026.

The company said it expects to grant underwriters an option to purchase up to an additional 15% of the ordinary shares at the public offering price, less the underwriting discount. All shares to be sold in the offering will be sold by the company.

TD Cowen is acting as lead book-running manager for the offering.

The company noted the offering is subject to market and other conditions, and there is no assurance as to whether or when the offering may be completed, or as to the actual size or terms.

A registration statement on Form F-3 relating to the offering was declared effective by the U.S. Securities and Exchange Commission on August 15, 2025. The preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on the SEC's website.

You May Also Be Interested In

• SOPHiA Genetics closes $57.5M public offering at $4.75 per share
• Definium Therapeutics to release Phase 3 MDD study results June 22
• uniQure reports early data from AMT-260 epilepsy gene therapy trial